- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 | 1 | GlobeNewswire (USA) | ||
| 14.05. | Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals | 3 | Seeking Alpha | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 13.05. | Journey Medical: Starker Gewinn pro Aktie, aber Umsatz enttäuscht | 9 | Investing.com Deutsch | ||
| 13.05. | Transcript: Journey Medical Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 13.05. | Journey Medical: EPS übertrifft Schätzungen um 0,05 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 13.05. | Journey Medical Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 283 | GlobeNewswire (Europe) | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| 06.05. | Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 | 2 | GlobeNewswire (USA) | ||
| 21.04. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi | 2 | GlobeNewswire (USA) | ||
| 26.03. | Journey Medical stock rating reiterated at Buy by H.C. Wainwright | 4 | Investing.com | ||
| 26.03. | Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand | 2 | Seeking Alpha | ||
| 25.03. | Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M | 1 | Seeking Alpha | ||
| 25.03. | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | 393 | GlobeNewswire (Europe) | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| 25.03. | Journey Medical Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 18.03. | Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 | 2 | GlobeNewswire (USA) | ||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 350 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| 12.08.25 | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 703 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,455 | +0,54 % | RBC stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Pfizer auf "Sector Perform" mit einem Kursziel von 25 US-Dollar belassen. Der Pharmakonzern habe positive Ergebnisse zweiter... ► Artikel lesen | |
| GILEAD SCIENCES | 112,74 | -1,17 % | AWSX der Telegram-Trader.de: Gilead Sciences überzeugt mit starkem Wachstum - Prognose Kerngeschäft steigt | ||
| ELI LILLY | 1.021,00 | +0,85 % | Novo Nordisk, Eli Lilly und Co. suchen den nächsten Milliardenmarkt - warum Zelltherapien plötzlich neue Einsatzgebiete erobern | ||
| VERTEX PHARMACEUTICALS | 422,15 | +0,52 % | Vertex Pharmaceuticals Inc. Profit Climbs In Q2 | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) announced earnings for its second quarter that Increases, from the same period last yearThe company's earnings came in... ► Artikel lesen | |
| INNOCAN PHARMA | 1,515 | +4,48 % | Innocan Pharma Corporation: Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust | Milestone underscores strong consumer confidence, exceptional product quality, and the Company's expanding presence in the U.S. consumer wellness marketHERZLIYA, Israel and CALGARY, Alberta... ► Artikel lesen | |
| EYEPOINT | 10,800 | +2,86 % | EyePoint, Inc.: EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) | - COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients --... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 264,00 | +0,76 % | LIGAND PHARMACEUTICALS INC - 8-K, Current Report | ||
| JAZZ PHARMACEUTICALS | 229,90 | +1,50 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results | View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-announces-second-quarter-2026-financial-results-302841455.html
► Artikel lesen | |
| UNITED THERAPEUTICS | 447,30 | -0,45 % | United Therapeutics Corp Bottom Line Climbs In Q2 | WASHINGTON (dpa-AFX) - United Therapeutics Corp (UTHR) announced a profit for its second quarter that Increased, from the same period last yearThe company's earnings totaled $333.0 million,... ► Artikel lesen | |
| OPKO HEALTH | 1,130 | -4,24 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health | Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:... ► Artikel lesen | |
| JAGUAR HEALTH | 0,986 | -6,10 % | Jaguar Health, Inc.: Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 | As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1 - Jaguar's two commercialized... ► Artikel lesen | |
| ROYALTY PHARMA | 50,61 | +1,25 % | Royalty Pharma Q2 Net Income Declines; Raises 2026 Guidance For Portfolio Receipts | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) reported that its second quarter net income attributable to Royalty Pharma declined to $18 million from $32 million, last year. Adjusted EBITDA... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| TG THERAPEUTICS | 43,100 | -0,23 % | TG THERAPEUTICS, INC. - 10-Q, Quarterly Report | ||
| BRIDGEBIO PHARMA | 72,04 | +1,52 % | BridgeBio Pharma, Inc.: BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-0,16 %) liegt der Kurs bei 6,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.